Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)

Key facts

Study ID

NCT01266876

Run by

Regeneron Pharmaceuticals

People needed

77

Starts

2011-01-01

Expected to finish

2011-11-01

Last updated by the study team

2015-09-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must meet the World Health Organization criteria for heFH
• Participants must be on a stable statin dose, with or without ezetimibe, for at least 6 weeks before screening
• Serum LDL-C levels ≥ 100 mg/dL at screening
• Willing to follow the NCEP ATPIII TLC diet, or an equivalent diet plan, starting at screening and continuing until the last study visit
• A negative urine/serum pregnancy test at each screening visit and start of the study, for women of childbearing potential
• Key Exclusion Criteria:
• Participants with homozygous FH (clinically or by previous genotyping)
• Use of a medication (other than a statin or EZE) to alter serum lipids within 42 days (6 weeks) before screening including, but not limited to:
• Fibrates
• Niacin (>500 mg/day)
• Omega-3 fatty acids (>1000 mg/day of DHA/EPA)
• Bile acid resins
• Use of nutraceuticals or OTC medications that may alter lipid levels that are not stable for at least 6 weeks before screening and are not planned to remain constant throughout the study. Examples include:
• Omega-3 fatty acids (≤1000 mg/day of DHA/EPA)
• Niacin (≤500 mg/day)
• Plant stanols, such as found in Benecol, flax seed oil, psyllium
• Red yeast rice
• Disorders known to influence lipid levels, such as nephrotic syndrome, significant liver disease, Cushing's disease, untreated hypothyroidism (patients on stable thyroid replacement for at least 12 weeks before the full screening visit, who are metabolically euthyroid by thyroid-stimulating hormone (TSH) testing are allowed)
• Use of thyroid medications (except for replacement therapy which has been stable for at least 12 weeks before the full screening visit)
• Fasting serum TG >350 mg/dL screening
• LDL apheresis within 12 months before screening

Where it is running

• Study site — Huntsville, Alabama, United States
• Study site — Mission Viejo, California, United States
• Study site — Newport Beach, California, United States
• Study site — Bridgeport, Connecticut, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Port Orange, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Kansas City, Kansas, United States
• Study site — Auburn, Maine, United States
• Study site — Biddeford, Maine, United States
• Study site — St Louis, Missouri, United States
• Study site — Concord, New Hampshire, United States
• Study site — Durham, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Nashville, Tennessee, United States
• Study site — Houston, Texas, United States
• Study site — Winnipeg, Manitoba, Canada
• Study site — London, Ontario, Canada
• Study site — Chicoutimi, Quebec, Canada
• Study site — Montreal, Quebec, Canada
• Study site — Saint Foy, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.